If marijuana is rescheduled from Schedule I to a lower drug schedule under the Controlled Substances Act before Jan 1, 2028, then the market resolves to Yes. If the DEA were to reschedule only certain cannabis derivatives or specific cannabinoids (e.g., move THC or a particular cannabis-derived pharmaceutical to a different schedule) without reclassifying marijuana/cannabis as a whole, that would not qualify as rescheduling marijuana for this contract. Ending the schedule altogether would resolve the market to Yes. This market will close and expire early if the event occurs.